The New England journal of medicine
04 04, 2019 380 (14) 1326-1335
Vol. 380, Issue 14, Medline Page 1326-1335
Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors.
In patients with acute major bleeding associated with the use of a factor Xa inhibitor, treatment with andexanet markedly reduced anti-factor Xa activity, and 82% of patients had excellent or good hemostatic efficacy at 12 hours, as adjudicated according to prespecified criteria. (Funded by Portola Pharmaceuticals; ANNEXA-4 ClinicalTrials.gov number, NCT02329327.).